IMPLANET Announces the Launch of Its Training Program in Advance of Marketing its JAZZ® Range in China
12 Décembre 2023 - 6:00PM
Business Wire
- First Chinese surgeon participation in IMPLANET’s JAZZ
Academy
- Registration of the JAZZ® range with the Chinese health
authorities is ongoing
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for
PEA-PME plans), a medical technology company specializing in
implants for orthopedic surgery and the distribution of
technological medical equipment, announces the launch of its
surgeon training program with a view to marketing its JAZZ® range
in China.
Ludovic Lastennet, IMPLANET’s Chief Executive Officer,
stated: “We are proud to welcome Professor Huanxiong Chen, Head of
the Hainan Medical University’s Department of Spine Surgery, for
two months. He is the first Chinese surgeon to receive training
related to the JAZZ® platform. This program includes immersion
training in French hospitals that use JAZZ® and are recognized for
their spine surgery expertise. This training is dispensed by the
JAZZ Academy, our structure devoted to training. This is a major
new step to best prepare the upcoming marketing of our JAZZ® range
in China by our partner Sanyou Medical. We are eagerly awaiting
feedback from the Chinese health authorities regarding the
registration of our products. Professor Chen should be able to
begin the first surgical interventions during the first quarter of
2024”.
Professor Huanxiong Chen, Department of Spine Surgery, Hainan
Medical University, added: “I am honored to be the first
Chinese surgeon trained by IMPLANET in the JAZZ® range. I’m
delighted to have this opportunity to talk with French surgeons
about their experience with JAZZ® and to discover the various
surgical indications. I hope to be able to use the JAZZ® range once
I return to China in my day-to-day work in pediatric and adult
surgery”. The JAZZ® Academy, helps surgeons expand their knowledge
of the JAZZ® range and sub-laminar techniques. During training,
different surgical strategies are addressed depending on
indications. Each session is supervised by a surgeon who is an
expert in this field and by an experienced technical team. During
his stay in France, which began in late November 2023, Professor
Chen will thus have an opportunity to participate in several spine
surgery operations performed in prominent French university
hospitals, including those in Paris (APH) and Lyon (HCL).
This first training of a Chinese surgeon in JAZZ® technologies
is one of the final stages before the marketing of IMPLANET’s JAZZ®
range is initiated in China, the world’s largest spine surgery
market by volume. As a reminder, the distribution of the JAZZ®
range by Sanyou Medical on the Chinese market is dependent on its
approval by the Chinese health authorities, whose initial feedback
is expected in 2024.
Upcoming financial
publication
- 2023 annual revenue, on January 15, 2024, after market
close
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that
manufactures high-quality implants for orthopedic surgery and
distributing medical technology equipment. Its activity revolves
around a comprehensive innovative solution for improving the
treatment of spinal pathologies (JAZZ®) complemented by the product
range offered by Orthopaedic & Spine Development (OSD),
acquired in May 2021 (thoraco-lumbar screws, cages and cervical
plates). Implanet’s tried-and-tested orthopedic platform is based
on the traceability of its products. Protected by four families of
international patents, JAZZ® has obtained 510(k) regulatory
clearance from the Food and Drug Administration (FDA) in the United
States, the CE mark in Europe and ANVISA approval in Brazil. In
2022, IMPLANET entered into a commercial, technological and
financial partnership with SANYOU MEDICAL, China's second largest
medical device manufacturer. IMPLANET employs 43 staff and recorded
a consolidated revenue of €8.0 million in 2022. Based near Bordeaux
in France, IMPLANET opened a US subsidiary in Boston in 2013.
IMPLANET is listed on the Euronext Growth market in Paris. For
further information, please visit www.Implanet.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231211399949/en/
IMPLANET Ludovic Lastennet, CEO David Dieumegard, CFO
Tél. : +33 (0)5 57 99 55 55 investors@Implanet.com
NewCap Investor Relations Mathilde Bohin Nicolas Fossiez
Tél.: +33 (0)1 44 71 94 94 Implanet@newcap.eu
NewCap Media Relations Arthur Rouillé Tél.: +33 (0)1 44
71 94 94 Implanet@newcap.eu
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024